Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)

The activity and toxicity profile of gefitinib in non-small cell lung cancer (NSCLC) patients aged 70 years or older has been only partially evaluated. The aim of this study was to evaluate the response rate and safety of gefitinib in elderly NSCLC patients. Elderly NSCLC patients pretreated with ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Cappuzzo, F, Bartolini, S, Ceresoli, G L, Tamberi, S, Spreafico, A, Lombardo, L, Gregorc, V, Toschi, L, Calandri, C, Villa, E, Crinò, L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395316/
https://www.ncbi.nlm.nih.gov/pubmed/14710211
http://dx.doi.org/10.1038/sj.bjc.6601470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395316/
https://www.ncbi.nlm.nih.gov/pubmed/14710211
http://dx.doi.org/10.1038/sj.bjc.6601470

Ejemplares similares